Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 81
- Registration Number
- NCT06361329
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06357182
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Northside Hospital, Inc.
- Registration Number
- NCT06337331
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: Asparaginase Erwinia chrysanthemiProcedure: Bone Marrow AspirationProcedure: Computed TomographyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: PrednisoloneDrug: DexamethasoneDrug: PrednisoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyDrug: LeucovorinProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 171
- Registration Number
- NCT06317662
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 147
- Registration Number
- NCT06317649
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT06311227
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT06284486
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06285890
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT06247540
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Cladribine Venetoclax in Monocytic AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 40
- Registration Number
- NCT06232655
- Locations
- 🇺🇸
Universtiy of Colorado Hospital, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.